

DOCKET NO.: ISIS0003-102 (ISPH-0522US.D1)**PATENT****In the Claims:**

The current status of all claims is listed below and supercedes all previous lists of claims.

Please add new claims 13-17 as follows:

1. (original) An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 90% homologous to SEQ ID NO:1, wherein the nucleic acid molecule encodes a polypeptide having RNase III activity.
2. (original) The isolated nucleic acid molecule of claim 1 comprising SEQ ID NO: 1.
3. (original) An isolated nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide which is at least 90% homologous to SEQ ID NO:2 wherein the polypeptide has RNase III activity.
4. (original) The isolated nucleic acid molecule of claim 3 which encodes a polypeptide comprising SEQ ID NO:2.
5. (original) A vector which comprises the nucleic acid molecule of claim 1 or claim 3.
6. (original) An isolated host cell comprising the vector of claim 5.
7. (original) The host cell of claim 6 wherein the host cell is a mammalian host cell.
8. (original) An isolated host cell comprising the nucleic acid molecule of claim 1 or claim 3.
9. (original) The host cell of claim 8 wherein the host cell is a mammalian host cell.

DOCKET NO.: ISIS0003-102 (ISPH-0522US.D1)**PATENT**

10. (original) A composition which comprises the nucleic acid molecule of claim 1 or claim 3 and a pharmaceutically acceptable carrier.
11. (original) A composition which comprises the vector of claim 5 and a pharmaceutically acceptable carrier.
12. (original) A method for producing a polypeptide comprising culturing the host cell of claim 8 under conditions in which the nucleic acid molecule is expressed, thereby producing a polypeptide.
13. (new) A cell having enhanced RNase III activity over an activity exhibited by a second cell, said second cell not enriched with respect to the amount or activity of RNase III polypeptide.
14. (new) The cell of claim 13 wherein said enhanced RNase III activity is detectable in the cell's nucleus.
15. (new) The cell of claim 13 wherein said enhanced RNase III activity is due to overexpression of RNase III.
16. (new) The cell of claim 13 wherein the RNase III polypeptide is provided through upregulation of endogenous production of the RNase III polypeptide.
17. (new) The cell of claim 13 wherein said enhanced RNase III activity is due to exogenously added RNase III.